Coyne Terrance P. 4

What Happened Terrance P. Coyne, EVP & Chief Financial Officer of Royalty Pharma (RPRX), sold a total of 34,791 Class A ordinary shares in open-market transactions on March 23, 2026, generating aggregate proceeds of $1,583,989. The reported weighted-average sale price was $45.53 per share; the trades consisted of 32,916 shares for $1,498,623 and 1,875 shares for $85,366. These were sales (not purchases) and are typically routine dispositions.

Key Details

• Transaction date: March 23, 2026 (filed on March 25, 2026 — filed timely within the Form 4 reporting window).
• Prices: weighted average $45.53; actual execution prices ranged $45.30 to $45.94 per share (seller can provide per-share breakdown on request).
• Total shares sold: 34,791; total proceeds: $1,583,989.
• Plan note: All reported sales were made under a pre-established 10b5-1 trading plan adopted August 8, 2025.
• Post-transaction ownership: the Form 4 does not state Coyne’s direct share count after these sales, but the filing’s remarks note that Coyne and family vehicles hold exchangeable interests equal to up to 6,448,180 Class A shares (via RPI US Partners 2019, LP) and 1,807,277 Class A-equivalent shares (via Class E shares of RPH, with vesting conditions).

Context A 10b5-1 plan indicates these sales were made according to a pre-arranged schedule or rules, which helps insulate the transactions from claims of trading on inside information. Sales are routine insider activity and do not by themselves indicate company performance or insider sentiment.